HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Friday, 14 November 2014

Rivaroxaban for the prevention of adverse outcomes in patients after the acute management of acute coronary syndrome…

…gets approval from NICE in their draft recommendation.  And, incidentally, it’s one of the rare examples where the ERG produced a lower ICER than the manufacturer.  In summary….

“The Committee concluded that rivaroxaban 2.5mg twice daily in combination with aspirin plus clopidogrel or with aspirin alone was more effective than aspirin plus clopidogrel or aspirin alone for preventing further cardiovascular deaths and myocardial infarction in people with acute coronary syndrome and raised cardiac biomarkers.

The Committee noted that the company’s base case ICER was £6,203 per QALY gained, and the ERG’s preferred base case estimate was £5,622 per QALY gained. It accepted that there is uncertainty about the validity of the results based on ATLAS-ACS 2-TIMI 51 because of the risk of bias resulting from missing data and informative censoring. However, The Committee considered that the ICERs presented were all within the range which could be considered cost effective and that adjusting for the various types of bias that might have occurred was unlikely to increase the ICER to the extent that it would become unacceptable.”

The ERG was ScHARR-TAG with the following researchers from HEDS… Abdullah Pandor, Daniel Pollard, Matt Stevenson and Anna Cantrell.